Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 57
Filter
1.
Int J Cardiol ; 343: 92-101, 2021 Nov 15.
Article in English | MEDLINE | ID: mdl-34437933

ABSTRACT

BACKGROUND AND PURPOSE: Assisted reproductive technologies (ART) induce premature vascular aging in human offspring. The related alterations are well-established risk factors for stroke and predictors of adverse stroke outcome. However, given the young age of the human ART population there is no information on the incidence and outcome of cerebrovascular complications in humans. In mice, ART alters the cardiovascular phenotype similarly to humans, thereby offering the possibility to study this problem. METHODS: We investigated the morphological and clinical outcome after ischemia/reperfusion brain injury induced by transient (45 min) middle cerebral artery occlusion in ART and control mice. RESULTS: We found that stroke volumes were almost 3-fold larger in ART than in control mice (P < 0.001). In line with these morphological differences, neurological performance assessed by the Bederson and RotaRod tests 24 and 48 h after artery occlusion was significantly worse in ART compared with control mice. Plasma levels of TNF-alpha, were also significantly increased in ART vs. control mice after stroke (P < 0.05). As potential underlying mechanisms, we identified increased blood-brain barrier permeability evidenced by increased IgG extravasation associated with decreased tight junctional protein claudin-5 and occludin expression, increased oxidative stress and decreased NO-bioactivity in ART compared with control mice. CONCLUSIONS: In wildtype mice, ART predisposes to significantly worse morphological and functional stroke outcomes, related at least in part to altered blood-brain barrier permeability. These findings demonstrate that ART, by inducing premature vascular aging, not only is a likely risk factor for stroke-occurrence, but also a mediator of adverse stroke-outcome. TRANSLATIONAL PERSPECTIVE: This study highlights that ART not only is a likely risk factor for stroke-occurrence, but also a mediator of adverse stroke-outcome. The findings should raise awareness in the ever-growing human ART population in whom these techniques cause similar alterations of the cardiovascular phenotype and encourage early preventive and diagnostic efforts.


Subject(s)
Brain Ischemia , Stroke , Animals , Blood-Brain Barrier , Fertilization in Vitro , Infarction, Middle Cerebral Artery/epidemiology , Mice , Stroke/epidemiology
2.
Sci Rep ; 9(1): 2173, 2019 02 18.
Article in English | MEDLINE | ID: mdl-30778120

ABSTRACT

Rheumatoid Arthritis (RA) is a chronic inflammatory disorder where incidence and severity of myocardial infarction are increased. Data on the incidence and outcome of stroke are conflicting. Thus, we investigated outcome after Ischemia/Reperfusion (I/R) brain injury in a mouse model of RA and assessed for the role of the tumour necrosis factor-α (TNF-α) inhibitor Infliximab herein. We used a TNF-α reliant mouse model of RA. RA and wildtype (WT) animals were treated with vehicle (RA/WT) or Infliximab (RA Infliximab) for 4 weeks, before undergoing I/R brain injury. RA-animals displayed larger strokes and poorer neurological performance. Immunohistochemistry on brain sections revealed increased numbers of resident and peripheral innate immune cells (microglia and macrophages); increased Blood-Brain-Barrier (BBB)-disruption; decreased levels of the tight junction proteins (TJPs) claudin-5 and occludin; increased expression of matrix-metalloproteinases (MMP)-3 and -9 and enhanced lipid peroxidation. Treatment with Infliximab corrected these alterations. We show that RA associates to worse stroke-outcome via exacerbated BBB degradation by decrease of the TJPs claudin-5 and occludin. We identified MMPs-3 and -9 and increased oxidative stress as potential mediators thereof. Increased numbers of resident and peripheral innate immune cells (microglia and macrophages) may in turn contribute to all these effects. Infliximab-treatment restored the phenotype of RA-mice to baseline. Our data provide evidence clearly linking RA to adverse stroke-outcome in mice and indicate an approved TNF-α inhibitor as a potential strategy to reduce stroke-burden in this setting.


Subject(s)
Arthritis, Experimental/complications , Arthritis, Rheumatoid/complications , Infliximab/therapeutic use , Stroke/drug therapy , Stroke/etiology , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Animals , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Blood-Brain Barrier , Brain Injuries/drug therapy , Brain Injuries/etiology , Brain Injuries/pathology , Female , Humans , Lipid Peroxidation , Macrophage Activation , Male , Mice , Mice, Inbred C57BL , Mice, Inbred CBA , Mice, Transgenic , Microglia/pathology , Reperfusion Injury/drug therapy , Reperfusion Injury/etiology , Reperfusion Injury/pathology , Stroke/pathology , Tumor Necrosis Factor-alpha/genetics
3.
Thromb Res ; 160: 9-13, 2017 Dec.
Article in English | MEDLINE | ID: mdl-29080550

ABSTRACT

INTRODUCTION: Whether clinical prediction rules for pulmonary embolism are accepted and used among general internal medicine residents remains uncertain. We therefore evaluated the frequency of use and acceptability of the Revised Geneva Score (RGS) and the Pulmonary Embolism Severity Index (PESI), and explored which factors were associated with rule use. MATERIALS/METHODS: In an online survey among general internal medicine residents from 10 Swiss hospitals, we assessed rule acceptability using the Ottawa Acceptability of Decision Rules Instrument (OADRI) and explored the association between physician and training-related factors and rule use using mixed logistic regression models. RESULTS: The response rate was 50.4% (433/859). Overall, 61% and 36% of the residents reported that they always or regularly use the RGS and the PESI, respectively. The mean overall OADRI score was 4.3 (scale 0-6) for the RGS and 4.1 for the PESI, indicating a good acceptability. Rule acceptability (odds ratio [OR] 6.19 per point, 95% confidence interval [CI] 3.64-10.51), prior training in emergency medicine (OR 5.14, CI 2.20-12.01), and availability of internal guidelines recommending RGS use (OR 4.25, CI 2.15-8.43) were associated with RGS use. Rule acceptability (OR 6.43 per point, CI 4.17-9.92) and rule taught at medical school (OR 2.06, CI 1.24-3.43) were associated with PESI use. CONCLUSIONS: The RGS was more frequently used than the PESI. Both rules were considered acceptable. Rule acceptability, prior training in emergency medicine, availability of internal guidelines, and rule taught at medical school were associated with rule use and represent potential targets for quality improvement interventions.


Subject(s)
Internal Medicine/trends , Internship and Residency/trends , Pulmonary Embolism/epidemiology , Adult , Female , Humans , Male , Prognosis , Risk Assessment , Risk Factors , Severity of Illness Index , Surveys and Questionnaires , Sweden , Young Adult
4.
J Thromb Haemost ; 15(11): 2165-2175, 2017 11.
Article in English | MEDLINE | ID: mdl-28834238

ABSTRACT

Essentials The long-term effects of VKORC1 and CYP2C9 variants on clinical outcomes remains unclear. We followed 774 patients ≥65 years with venous thromboembolism for a median duration of 30 months. Patients with CYP2C9 variants are at increased risk of death and non-major bleeding. Patients with genetic variants have a slightly lower anticoagulation quality only. SUMMARY: Background The long-term effect of polymorphisms of the vitamin K-epoxide reductase (VKORC1) and the cytochrome P450 enzyme gene (CYP2C9) on clinical outcomes remains unclear. Objectives We examined the association between CYP2C9/VKORC1 variants and long-term clinical outcomes in a prospective cohort study of elderly patients treated with vitamin K antagonists for venous thromboembolism (VTE). Methods We followed 774 consecutive patients aged ≥ 65 years with acute VTE from nine Swiss hospitals for a median duration of 30 months. The median duration of initial anticoagulant treatment was 9.4 months. The primary outcome was the time to any clinical event (i.e. the composite endpoint of overall mortality, major and non-major bleeding, and recurrent VTE. Results Overall, 604 (78%) patients had a CYP2C9 or VKORC1 variant. Three hundred and thirty-four patients (43.2%) had any clinical event, 119 (15.4%) died, 100 (12.9%) had major and 167 (21.6%) non-major bleeding, and 100 had (12.9%) recurrent VTE. After adjustment, CYP2C9 (but not VKORC1) variants were associated with any clinical event (hazard ratio [HR], 1.34; 95% confidence interval [CI], 1.08-1.66), death (HR, 1.74; 95% CI, 1.19-2.52) and clinically relevant non-major bleeding (sub-hazard ratio [SHR], 1.39; 95% CI, 1.02-1.89), but not with major bleeding (SHR, 1.03; 95% CI, 0.69-1.55) or recurrent VTE (SHR, 0.95; 95% CI, 0.62-1.44). Patients with genetic variants had a slightly lower anticoagulation quality. Conclusions CYP2C9 was associated with long-term overall mortality and non-major bleeding. Although genetic variants were associated with a slightly lower anticoagulation quality, there was no relationship between genetic variants and major bleeding or VTE recurrence.


Subject(s)
Anticoagulants/therapeutic use , Blood Coagulation/drug effects , Cytochrome P-450 CYP2C9/genetics , Pharmacogenomic Variants , Venous Thromboembolism/drug therapy , Vitamin K Epoxide Reductases/genetics , Vitamin K/antagonists & inhibitors , Age Factors , Aged , Anticoagulants/adverse effects , Cytochrome P-450 CYP2C9/metabolism , Female , Hemorrhage/chemically induced , Humans , Male , Pharmacogenetics , Prospective Studies , Recurrence , Risk Factors , Switzerland , Time Factors , Treatment Outcome , Venous Thromboembolism/blood , Venous Thromboembolism/genetics , Venous Thromboembolism/mortality , Vitamin K Epoxide Reductases/metabolism
5.
J Thromb Haemost ; 15(1): 47-56, 2017 01.
Article in English | MEDLINE | ID: mdl-27790827

ABSTRACT

Essentials The role of omega-3 fatty acids (n-3 FAs) in recurrent venous thromboembolism (VTE) is unknown. Association of n-3 FAs with recurrent VTE or total mortality was investigated in 826 patients. Whole blood n-3 FAs were inversely correlated with recurrent VTE or total mortality. Major and non-major bleeding was not increased in patients with higher levels of n-3 FAs. SUMMARY: Background The role of omega-3 fatty acids (n-3 FAs) in recurrent venous thromboembolism (VTE) remains unknown. Objectives To investigate the association of n-3 FAs with recurrent VTE or total mortality at 6 months and 3 years. Methods N-3 FAs were assessed in 826 patients aged ≥ 65 years, categorized into low, medium and high based on the 25th and 75th percentile. Mean follow-up was 29 months. Results At 6 months, subjects with medium (adjusted hazard ratio [HR], 0.37; 95% confidence interval [CI], 0.22-0.62) and high n-3 FA levels (adjusted HR, 0.36; 95% CI, 0.20-0.67) were less likely to develop recurrent VTE or total mortality, compared with those with low n-3 FAs. At 3 years, medium levels (adjusted HR, 0.67; 95% CI, 0.47-0.96) were associated with lower risk of recurrent VTE or total mortality. As compared with low n-3 FAs, the adjusted sub-hazard ratio [SHR] of recurrent VTE was 0.39 (95% CI, 0.15-0.99) in patients with medium and 0.17 (95% CI, 0.03-0.82) in patients with high n-3 FAs. The cumulative incidence of recurrent VTE was lower in the medium and high n-3 FA groups as compared with the low n-3 FA groups, but seems to have worn off after 3 years. The incidence of major and non-major bleeding was not greater in the high n-3 FA group. Conclusion Higher levels of n-3 FAs were associated with a lower risk of recurrent VTE or total mortality in elderly patients with VTE, but not with greater bleeding risk.


Subject(s)
Fatty Acids, Omega-3/blood , Venous Thromboembolism/epidemiology , Acute Disease , Aged , Aged, 80 and over , Female , Follow-Up Studies , Hemorrhage , Humans , Kaplan-Meier Estimate , Male , Mortality , Neoplasms/complications , Proportional Hazards Models , Prospective Studies , Pulmonary Embolism/drug therapy , Recurrence , Risk Factors
7.
J Thromb Haemost ; 14(4): 685-94, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26816339

ABSTRACT

BACKGROUND: Venous thromboembolism (VTE) and subclinical thyroid dysfunction (SCTD) are both common in elderly patients. SCTD has been related to a hypercoagulable state and an increased thromboembolic risk. However, prospective data on the relationship between SCTD and VTE are lacking. OBJECTIVES: To investigate the relationship between SCTD and recurrent VTE (rVTE), all-cause mortality, and thrombophilic biomarkers. Patients Elderly patients with VTE were studied. METHODS: In a prospective multicenter cohort, thyroid hormones and thrombophilic biomarkers were measured 1 year after acute VTE, as both may be influenced by acute thrombosis. We defined subclinical hypothyroidism (SHypo) as elevated thyroid-stimulating hormone (TSH) levels (4.50-19.99 mIU L(-1) ), and subclinical hyperthyroidism (SHyper) as TSH levels of < 0.45 mIU L(-1) , both with normal free thyroxine levels. Outcomes were incidence of rVTE and overall mortality during follow-up starting after the 1-year blood sampling. RESULTS: Of 561 participants (58% with anticoagulation), 6% had SHypo and 5% had SHyper. After 20.8 months of mean follow-up, 9% developed rVTE and 10% died. The rVTE incidence rate was 7.2 (95% confidence interval [CI] 2.7-19.2) per 100 patient-years in SHypo participants, 0.0 (95% CI 0.0-7.6) in SHyper participants, and 5.9 (95% CI 4.4-7.8) in euthyroid participants. In multivariate analyses, the sub-hazard ratio for rVTE was 0.00 (95% CI 0.00-0.58) in SHyper participants and 1.50 (95% CI 0.52-4.34) in SHypo participants as compared with euthyroid participants, without increased levels of thrombophilic biomarkers. SHyper (hazard ratio [HR] 0.80, 95% CI 0.23-2.81) and SHypo (HR 0.99, 95% CI 0.30-3.29) were not associated with mortality. CONCLUSION: In elderly patients, SHyper may be associated with lower rVTE risks. SHypo showed a non-statistically significant pattern of an association with rVTE, without increased mortality or differences in thrombophilic biomarkers.


Subject(s)
Thyroid Diseases/complications , Thyroid Diseases/physiopathology , Venous Thromboembolism/complications , Venous Thromboembolism/physiopathology , Aged , Aged, 80 and over , Biomarkers/blood , Blood Coagulation , Female , Humans , Hyperthyroidism/physiopathology , Hypothyroidism/physiopathology , Male , Middle Aged , Prospective Studies , Risk Factors , Thromboembolism , Thrombophilia/blood , Thrombosis/physiopathology , Thyroid Diseases/mortality , Thyroid Gland/physiopathology , Thyrotropin/blood , Thyroxine/blood , Treatment Outcome , Venous Thromboembolism/mortality
8.
Eur Heart J ; 36(25): 1590-600, 2015 Jul 01.
Article in English | MEDLINE | ID: mdl-25904764

ABSTRACT

AIM: Constitutive genetic deletion of the adaptor protein p66(Shc) was shown to protect from ischaemia/reperfusion injury. Here, we aimed at understanding the molecular mechanisms underlying this effect in stroke and studied p66(Shc) gene regulation in human ischaemic stroke. METHODS AND RESULTS: Ischaemia/reperfusion brain injury was induced by performing a transient middle cerebral artery occlusion surgery on wild-type mice. After the ischaemic episode and upon reperfusion, small interfering RNA targeting p66(Shc) was injected intravenously. We observed that post-ischaemic p66(Shc) knockdown preserved blood-brain barrier integrity that resulted in improved stroke outcome, as identified by smaller lesion volumes, decreased neurological deficits, and increased survival. Experiments on primary human brain microvascular endothelial cells demonstrated that silencing of the adaptor protein p66(Shc) preserves claudin-5 protein levels during hypoxia/reoxygenation by reducing nicotinamide adenine dinucleotide phosphate oxidase activity and reactive oxygen species production. Further, we found that in peripheral blood monocytes of acute ischaemic stroke patients p66(Shc) gene expression is transiently increased and that this increase correlates with short-term neurological outcome. CONCLUSION: Post-ischaemic silencing of p66(Shc) upon reperfusion improves stroke outcome in mice while the expression of p66(Shc) gene correlates with short-term outcome in patients with ischaemic stroke.


Subject(s)
Brain Injuries/prevention & control , Gene Silencing/physiology , Reperfusion Injury/prevention & control , Shc Signaling Adaptor Proteins/genetics , Stroke/prevention & control , Aged , Aged, 80 and over , Analysis of Variance , Animals , Blood-Brain Barrier/physiology , Case-Control Studies , Cells, Cultured , Claudin-5/drug effects , Endothelial Cells/physiology , Female , Gene Expression , Gene Knockdown Techniques , Humans , Infarction, Middle Cerebral Artery , Ischemic Postconditioning/methods , Male , Mice, Inbred C57BL , Microcirculation/physiology , Middle Aged , RNA, Messenger/metabolism , RNA, Small Interfering/pharmacology , Reactive Oxygen Species/pharmacology , Shc Signaling Adaptor Proteins/physiology , Src Homology 2 Domain-Containing, Transforming Protein 1 , Treatment Outcome
9.
Thromb Haemost ; 111(3): 531-8, 2014 Mar 03.
Article in English | MEDLINE | ID: mdl-24226257

ABSTRACT

There is a need to validate risk assessment tools for hospitalised medical patients at risk of venous thromboembolism (VTE). We investigated whether a predefined cut-off of the Geneva Risk Score, as compared to the Padua Prediction Score, accurately distinguishes low-risk from high-risk patients regardless of the use of thromboprophylaxis. In the multicentre, prospective Explicit ASsessment of Thromboembolic RIsk and Prophylaxis for Medical PATients in SwitzErland (ESTIMATE) cohort study, 1,478 hospitalised medical patients were enrolled of whom 637 (43%) did not receive thromboprophylaxis. The primary endpoint was symptomatic VTE or VTE-related death at 90 days. The study is registered at ClinicalTrials.gov, number NCT01277536. According to the Geneva Risk Score, the cumulative rate of the primary endpoint was 3.2% (95% confidence interval [CI] 2.2-4.6%) in 962 high-risk vs 0.6% (95% CI 0.2-1.9%) in 516 low-risk patients (p=0.002); among patients without prophylaxis, this rate was 3.5% vs 0.8% (p=0.029), respectively. In comparison, the Padua Prediction Score yielded a cumulative rate of the primary endpoint of 3.5% (95% CI 2.3-5.3%) in 714 high-risk vs 1.1% (95% CI 0.6-2.3%) in 764 low-risk patients (p=0.002); among patients without prophylaxis, this rate was 3.2% vs 1.5% (p=0.130), respectively. Negative likelihood ratio was 0.28 (95% CI 0.10-0.83) for the Geneva Risk Score and 0.51 (95% CI 0.28-0.93) for the Padua Prediction Score. In conclusion, among hospitalised medical patients, the Geneva Risk Score predicted VTE and VTE-related mortality and compared favourably with the Padua Prediction Score, particularly for its accuracy to identify low-risk patients who do not require thromboprophylaxis.


Subject(s)
Research Design/statistics & numerical data , Venous Thromboembolism/diagnosis , Venous Thromboembolism/epidemiology , Aged , Female , Follow-Up Studies , Hospitalization , Humans , Male , Middle Aged , Predictive Value of Tests , Prognosis , Prospective Studies , Research Design/standards , Risk Assessment , Survival Analysis , Switzerland , Venous Thromboembolism/mortality
10.
Infection ; 40(1): 57-62, 2012 Feb.
Article in English | MEDLINE | ID: mdl-21956456

ABSTRACT

OBJECTIVE: To double the vaccination rates of hospital employees from 20 to 40% by specific interventions over a 5-year period (2003-2007). The secondary endpoint was to compare the effects of the avian influenza in 2005 (intervention period) and the H1N1 influenza pandemic in 2009 (follow-up period, 2008-2009) on vaccination rates. DESIGN, SETTING, AND PARTICIPANTS: Free vaccination and its intensive propagation from 2003-2007 in a 400-bed teaching hospital with 1,687 hospital employees. Annual vaccination rates were obtained from 2003 through 2009. MAIN OUTCOME MEASUREMENTS: Yearly vaccination rates for the intervention period from 2003-2007 and the observational follow-up period of 2008-2009. RESULTS: The overall rate for seasonal influenza vaccination changed non-significantly during the intervention period from 20% in 2003 to 27% in 2007. At the end of the follow-up period in 2009, the vaccination rate was 26%, which was not significantly higher compared with that in 2003. Physicians interestingly increased from 34% in 2003 to 62% in 2007 and to 66% in 2009 (p < 0.001), while nurses dropped non-significantly from an already low proportion of 18% in 2003 to 15% in 2007 and to 16% in 2009 for seasonal influenza vaccination. The difference between nurses and doctors in 2007 is highly significant (p < 0.001). In the year of the avian influenza threat (2005), a significant increase was observed (30 vs. 20%, p < 0.001). This observation was seen again in 2009 (influenza A/H1N1v pandemic), during which the H1N1 vaccine uptake was 33% (p < 0.001, compared to seasonal flu vaccine in 2003). CONCLUSIONS: Overall, the vaccination rates did not increase over the 7-year study period. Interventions were successful for physicians but not for nurses. The vaccine uptake was significantly higher during the threat of avian influenza and the influenza A/H1N1v pandemic.


Subject(s)
Influenza Vaccines/administration & dosage , Influenza, Human/prevention & control , Personnel, Hospital/psychology , Vaccination/statistics & numerical data , Attitude of Health Personnel , Female , Follow-Up Studies , Hospitals, Teaching , Humans , Influenza A Virus, H1N1 Subtype/immunology , Male , Nurses/psychology , Nurses/statistics & numerical data , Personnel, Hospital/statistics & numerical data , Physicians/psychology , Physicians/statistics & numerical data , Seasons , Switzerland
11.
Swiss Med Wkly ; 138(31-32): 459-65, 2008 Aug 09.
Article in English | MEDLINE | ID: mdl-18690559

ABSTRACT

AIM OF THE STUDY: To analyse the costs of stroke in the first year covered by insurance companies and to correlate them with the clinical outcome data. METHODS: We contacted the insurance companies of 172 consecutive stroke patients of a single institution cohort for a detailed report of the stroke costs. A complete data set over one year was obtained from 131 patients (76%). RESULTS: Severity of stroke was significantly associated with increasing total costs (p = 0.0002). The rehabilitation clinic made up 37% of the total costs followed by nursing home with 21% and acute hospital with 21%. Mean cost of stroke per patient was 31,115 CHF in the first year. Costs per patient for inpatient rehabilitation were similar to those for the nursing home after one year; however, the Barthel-index of patients with inpatient rehabilitation increased by 42 +/- 29 points as compared to patients without inpatient rehabilitation by 23 +/- 26 points (p <0.05), and 86% resp. 81% of patients with inpatient stroke rehabilitation lived independently after 6 and 12 months respectively. CONCLUSIONS: The high level of independence after inpatient stroke rehabilitation underlines the importance of patient selection and/or rehabilitation. Therefore, long-term stroke costs may be significantly reduced by an early and careful triage in the case management after stroke and a case-dependent investment in initial costly appearing inpatient rehabilitation.


Subject(s)
Costs and Cost Analysis , Hospitalization/economics , Inpatients , Stroke Rehabilitation , Stroke/economics , Triage , Aged , Cohort Studies , Cost-Benefit Analysis , Female , Health Care Costs , Health Status Indicators , Humans , Male , Prospective Studies , Stroke/drug therapy , Switzerland , Time Factors
13.
Thromb Res ; 118(2): 229-34, 2006.
Article in English | MEDLINE | ID: mdl-16266742

ABSTRACT

BACKGROUND/OBJECTIVES: Bleeding problems during laparoscopic surgery are infrequent. We hypothesised that increased abdominal pressure during the application of the pneumoperitoneum would lead to an increased release of endogenous vasopressin which could then contribute to the hemostasis by increasing platelet reactivity, FVIII and von Willebrand-factor. PATIENTS AND METHODS: We compared the vasopressin levels, the platelet function as measured by the PFA-100-test, aPTT and FVIII in 39 consecutive patients who underwent elective hysterectomy (20 with the laparoscopic and 19 with the conventional, "open" method). Blood was sampled the day before surgery and 2, 4 and 72 h after the induction of anaesthesia. RESULTS: After two hours, the PFA-100 closure times with collagen/ADP decreased to lower levels in the laparoscopic group (from 93 +/- 22 to 82 +/- 20, mean +/- SD) and even further down to 65 +/- 13 s (compared to 82 +/- 20 s) (p = 0.024)) four hours after the beginning of surgery. Vasopressin levels and F VIII increased in both groups but there was no significant difference between the groups (21 vs. 17.8 pmol/l for vasopressin, differences of the mean). Bleeding was minimal, with a trend to lower Hb-levels in the laparotomy group. CONCLUSIONS: The procedural difference of laparoscopic vs. open hysterectomy appears to enhance platelet reactivity by other mechanisms than increased vasopressin levels and may contribute to an enhanced hemostatic competence in laparoscopic surgery.


Subject(s)
Hysterectomy/methods , Laparoscopy/methods , Platelet Function Tests/methods , Adult , Blood Platelets/physiology , Confidence Intervals , Factor VIII/analysis , Female , Humans , Middle Aged , Partial Thromboplastin Time/methods , Platelet Count , Time Factors , Vasopressins/blood
14.
Ther Umsch ; 62(9): 619-24, 2005 Sep.
Article in German | MEDLINE | ID: mdl-16218498

ABSTRACT

Until the 19th and the early 20th century, milk and milk products, particularly of alpine origins, seemed of special nutritional and health value and were highly recommended for the therapy resp. the therapeutic adjunct of various diseases, particularly for pulmonary tuberculosis. More recently, the association of saturated fat intake and arteriosclerosis led to the reduced use of milk and cheese resp. to the introduction of low-fat milk products. Again, alpine milk and cheese seem to differ somewhat from the others, since they appear to contain 4 times more alpha linolenic acid, three times more conjugated linoleic acid, a lower n-6:n-3 ratio, more total n-3 fatty acids and less palmitic acid as a measure of total saturated fat compared to cheese produced with silage feed in the lowlands (e.g. english cheddar). Even cheese from cows fed with linseed supplementations did not reach the n-3 concentrations of the alpine probes. Thus, alpine milk products from cows kept traditionally, and fed predominantly with alpine grass seem to have an interesting cardiovascular and possibly an economically favourable potential.


Subject(s)
Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/prevention & control , Cheese/statistics & numerical data , Diet Therapy/methods , Food, Organic/statistics & numerical data , Risk Assessment/methods , Risk Reduction Behavior , Altitude , Health Behavior , Humans , Practice Guidelines as Topic , Practice Patterns, Physicians' , Risk Factors , Switzerland/epidemiology
16.
Ther Umsch ; 60(1): 15-8, 2003 Jan.
Article in German | MEDLINE | ID: mdl-12638472

ABSTRACT

Many randomized trials have shown aspirin as an effective antiplatelet drug for the secondary prevention of cardiovascular events. The NNT (number needed to treat) to prevent 1 vascular event is about 25. The NNH (number needed to harm) inducing one cerebral bleeding is about 1'000, to provoke one severe extracerebral bleeding about 100-200. The primary prevention can be recommended only for high risk patients for cardiovascular events (annual risk of 1-1.5% or more), calculated on the basis of the Framingham data, the Sheffield tables or in analysis of U.S. Preventive Services Task Force. The mechanisms of action, interactions and the "aspirin-resistance" are briefly discussed.


Subject(s)
Aspirin/therapeutic use , Fibrinolytic Agents/therapeutic use , Platelet Aggregation Inhibitors/therapeutic use , Administration, Oral , Adult , Age Factors , Aged , Anticoagulants/administration & dosage , Anticoagulants/therapeutic use , Aspirin/administration & dosage , Aspirin/adverse effects , Cardiovascular Diseases/prevention & control , Diabetes Complications , Diabetes Mellitus/drug therapy , Drug Interactions , Drug Therapy, Combination , Female , Fibrinolytic Agents/administration & dosage , Fibrinolytic Agents/adverse effects , Hemorrhage/chemically induced , Humans , Male , Platelet Aggregation Inhibitors/administration & dosage , Platelet Aggregation Inhibitors/adverse effects , Primary Prevention , Randomized Controlled Trials as Topic , Risk Factors , Time Factors
17.
Thromb Haemost ; 88(5): 745-9, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12428088

ABSTRACT

In order to prospectively evaluate the predictive value of coagulation markers such as the fibrin Ddimer for survival of cancer patients, we analyzed their role in a prospective study at a University Hospital Institute of Medical Oncology. 268 consecutive outpatients with cancer were included, 72 in remission and 196 with active disease. All cause mortality in relation to the marker levels was measured. 99/268 patients died during the observation period of 4,484 patient months (mean: 17 months). Patients with active disease had a significant, 1.5-5-fold increased marker concentration compared to patients in remission. When analyzed in quartiles, the data showed a lower than predicted death rate in the first quartile and a significantly elevated mortality in the fourth marker quartile. The odds ratio for death predicted by the fibrin monomer (FM) in the fourth vs. the first quartile was 4.1 (95% C.I.: 1.7-9.7) and p = 0.005 for the multivariate analysis of the markers. We conclude that a single determination of coagulation markers, particularly of TAT, FM, and Ddimer is sufficient to strongly predict survival in cancer patients over the following 1-3 years.


Subject(s)
Blood Coagulation , Neoplasms/mortality , Antithrombin III , Biomarkers/blood , Case-Control Studies , Female , Fibrin/analysis , Fibrin Fibrinogen Degradation Products/analysis , Humans , Male , Neoplasms/blood , Neoplasms/diagnosis , Odds Ratio , Peptide Hydrolases/blood , Predictive Value of Tests , Prognosis , Prospective Studies , Survival Analysis , Survival Rate
18.
Thromb Res ; 103(2): 123-33, 2001 Jul 15.
Article in English | MEDLINE | ID: mdl-11457470

ABSTRACT

The purpose of this study was to determine if the results obtained in platelet function tests and whole blood perfusions are associated with those in platelet function analyser (PFA)-100. We used collagen type I monomers and fibrils to analyse the distinct roles of glycoprotein (GP) Ia/IIa and other collagen receptors in flowing blood under a high shear rate (1600/s) and in aggregation studies. Also, anticoagulation [citrate vs. D-phenylalanyl-1-prolyl-1 arginine chloromethyl ketone (PPACK)] was varied to enhance the functions of GP Ia/IIa, since it has been shown that the cation-poor environment of citrated blood impairs GP Ia/IIa-dependent platelet recruitment. Large interindividual variability (45-fold) was detected in deposition of platelets in whole blood perfusions over collagen monomers, whereas this variation was only fourfold in fibrils. In PFA, this variation was reduced to 2.5-fold. However, platelet deposition on monomers is associated with epinephrine-enhanced PFA (r=-.49, P<.03), whereas platelet deposition on fibrils is correlated with adenosine diphosphate (ADP)-enhanced PFA (r=-.47, P<.05), suggesting a distinct synergism between epinephrine and monomers (GP Ia/IIa) as well as ADP with fibrils (other collagen receptors). Donors with 807 C/C polymorphism of GP Ia (n=14) had longer lag phase in aggregation experiments compared with C/T (n=7) both by monomers and fibrils (P<.04), but these polymorphisms with their mild impact on GP Ia/IIa activity did not markedly differ in other tests. In conclusion, the results obtained in perfusion studies and PFA experiments correlated, but PFA fails to reveal the large-scale variability related to collagen-induced platelet responses.


Subject(s)
Blood Platelets/drug effects , Collagen/pharmacology , Platelet Aggregation/drug effects , Platelet Function Tests/instrumentation , Adenosine Diphosphate/pharmacology , Adult , Aged , Amino Acid Chloromethyl Ketones/pharmacology , Anticoagulants/pharmacology , Citric Acid/pharmacology , Collagen/chemistry , Drug Synergism , Epinephrine/pharmacology , Female , Genetic Variation , Humans , Integrins/drug effects , Integrins/physiology , Male , Middle Aged , Perfusion , Platelet Activation/drug effects , Polymorphism, Genetic , Receptors, Collagen , Reproducibility of Results , Rheology , Stress, Mechanical
20.
Swiss Med Wkly ; 131(45-46): 653-8, 2001 Dec 01.
Article in English | MEDLINE | ID: mdl-11835114

ABSTRACT

QUESTIONS UNDER STUDY: Diagnostic strategies in venous thromboembolism (VTE) are subject to controversy and rapid change and are dependent on the availability of the specific tests. The aim was to critically analyse the diagnostic procedures in patients with VTE at an intermediate size, non-university hospital. METHODS: The diagnostic work up of 270 consecutive patients with suspected VTE disorders was analysed prospectively and the therapeutic decisions were monitored and compared with the actually implemented new standard evaluation which consists of a sequential application of the diagnostic tools (clinical probability, D-dimer compression ultrasound V/Q lung scan or CT). The patients were followed clinically for at least three months. RESULTS: 50% of the 55 patients with suspected deep vein thrombosis (DVT) and 35% of the 215 patients with suspected pulmonary embolism (PE) were found positive and were anticoagulated. The overall number of patients being anticoagulated was not significantly changed by the new procedure but approximately 30% of the additional examinations inclusive V/Q-scans, spiral CT and compression ultrasound or phlebography could be saved. Our study and the follow up after the therapeutic decision indicate that 92% of the patients can be clearly and safely allocated, while the remainders are managed according to an essentially clinical decision. CONCLUSIONS: The vast majority (>90%) of the patients can be clearly diagnosed as positive or negative with the strategy presently used. A minority still requires an "overall decision". Our modified approach results in considerable cost savings.


Subject(s)
Diagnostic Imaging/statistics & numerical data , Hospitals, Urban/statistics & numerical data , Pulmonary Embolism/diagnosis , Thromboembolism/diagnosis , Venous Thrombosis/diagnosis , Adult , Aged , Aged, 80 and over , Anticoagulants/administration & dosage , Diagnostic Imaging/economics , Female , Humans , Incidence , Male , Middle Aged , Prospective Studies , Pulmonary Embolism/epidemiology , Risk Factors , Sensitivity and Specificity , Severity of Illness Index , Survival Rate , Switzerland/epidemiology , Thromboembolism/epidemiology , Tomography, X-Ray Computed/statistics & numerical data , Ultrasonography/methods , Ultrasonography/statistics & numerical data , Venous Thrombosis/epidemiology , Venous Thrombosis/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...